...the amount of active substance in circulation. TMX-201 is under investigation as a vaccine adjuvant. TMX-202...

...agonist TMX-102 is in Phase II testing to treat bladder cancer. The company's TLR7 agonist TMX-202...

...at developing new topical treatments for skin cancer based on a foam formulation of Telormedix's TMX-202...
...for skin cancer, actinic keratosis and genital warts by combining the target-specific binding properties of TMX-202...
...also includes academic partners Charite - Universitatsmedizin Berlin and the German Cancer Research Center . TMX-202...